Showing results (251-260 of 586) with videos related to
Sort By:
Pageof 59
American Heart Journal|April 1, 2009
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trialStefan James, Axel Akerblom, Christopher P Cannon, et al.European Heart Journal|May 10, 2020
Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trialMichael Böhm, Martina Brueckmann, John W Eikelboom, et al.Circulation|December 27, 2011
Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 trials (FIR)Peter Damman, Lars Wallentin, Keith A A Fox, et al.American Heart Journal|December 13, 2005
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes, Shamir R Mehta, Salim Yusuf, et al.Journal of the American Heart Association|July 12, 2014
Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACERHarvey D White, Zhen Huang, Pierluigi Tricoci, et al.Platelets|June 2, 2021
Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudyThomas A Nelson, William A E Parker, Tatevik Ghukasyan Lakic, et al.Clinical Chemistry|May 24, 2013
Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet Inhibition and Patient Outcomes (PLATO) studyAxel Åkerblom, Lars Wallentin, Anders Larsson, et al.European Heart Journal|February 5, 2008
The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trialRon J G Peters, Campbell Joyner, Jean-Pierre Bassand, et al.Annals of Internal Medicine|September 6, 2007
Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromesKeith A A Fox, Jean-Pierre Bassand, Shamir R Mehta, et al.Journal of Epidemiology and Community Health|April 16, 2005
Are international differences in the outcomes of acute coronary syndromes apparent or real? A multilevel analysisWei-Ching Chang, William K Midodzi, Cynthia M Westerhout, et al.Pageof 59